Keep Current with the Latest in Cell Biology Research

CSF1R+ Myeloid-Monocytic Cells Drive CAR-T Cell Resistance in Aggressive B Cell Lymphoma

[Cancer Cell] To elucidate factors associated with CAR-T therapy resistance, investigators conducted high-dimensional analyses of pre- and post-CAR-T cell specimens.

Design and Evaluation of Biodegradable Self-Immolative Lipids for RNA Delivery

[Advanced Healthcare Materials] A new family of ionizable cationic lipids called “Self-Immolative Lipids” is reported. This innovative lipid architecture was designed to overcome a critical challenge in non-viral gene therapy: the need for a delivery vector that is both efficacious and stable during biodistribution while remaining biodegradable upon reaching the target cell.

Somatic Gene Delivery Faithfully Recapitulates a Molecular Spectrum of High-Risk Sarcomas

[Nature Communications] Scientists described the development of a genetically-controlled, yet versatile mouse modeling platform allowing delivery of different genetic lesions by muscle electroporation in wildtype mice.

Neonatal Systemic Gene Therapy Restores Cardiorespiratory Function in a Rat Model of Pompe Disease

[Molecular Therapy] A novel Pompe rat model was used to test the hypothesis that neonatal gene therapy with adeno-associated virus serotype 9 restores cardiorespiratory neuromuscular function across the lifespan.

Gene Therapy with Covalently-Closed-End AAV Vector for Spinal Muscular Atrophy

[Molecular Therapy] Investigators reported first-in-human experience with a covalently closed-end adeno-associated virus vector. High quality clinical grade cceAAV vector based on AAV9 produced in 200 liters of suspension 293 cells with a total yield of 4.3 × 1016 vector genomes.

Enhancing Anti-Tumor Immunity of Natural Killer Cells through Targeting IL-15R Signaling

[Cancer Cell] Researchers performed genome-wide CRISPR screens to reveal the complete IL-15R signaling mechanism in natural killer cells and discovered that ubiquitin-dependent IL-15R degradation is the dominant mechanism restraining IL-15R signaling.

Enhancement of CRISPR-Cas12a System through Universal Circular RNA Design

[Cell Reports Methods] Scientists developed a light-triggerable circular RNA system for dynamic LbCas12a regulation. By employing circular CRISPR guide RNA (crRNA) or a split circular universal direct repeat region with a replaceable spacer, they resolved the incompatibility between isothermal amplification and CRISPR detection.

Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment

[Clinical Cancer Research] The authors write a foundational overview of the classification of cell and gene therapy in treating solid tumors and explore how it targets the cross-talk between cancer cells and the tumor immune microenvironment from cellular and molecular perspectives.

Mesoblast Maintains Momentum with FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults with GvHD

[Mesoblast (GlobeNewswire)] Mesoblast provided an update on continued momentum with US FDA regarding both accelerated approval pathway for Revascor® in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation, and label extension for Ryoncil® in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

[Teva Pharmaceuticals] Teva Pharmaceuticals and Fosun Pharma announced that they have entered into strategic partnership for the development of investigational TEV-56278, an anti-PD1 therapy in Phase I for the treatment of cancer, including melanoma.

Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales

[Galderma (BioSpace)] Galderma announced that nemolizumab has been recommended for routine funding on the National Health Service in England and Wales for moderate-to-severe atopic dermatitis in final draft guidance from the National Institute for Health and Care Excellence.

Nociceptor-Derived CGRP Enhances Dermal Type I Conventional Dendritic Cell Function to Drive Autoreactive CD8+ T Cell Responses in Vitiligo

[Immunity] Deletion of Nav1.8+ nociceptors, cDC1-specific ablation of the CGRP receptor, or treatment with a CGRP receptor antagonist abrogated CD8+ T cell autoreactivity and prevented skin depigmentation in a mouse model of vitiligo.

Stay up-to-date with your field!

Subscribe for free science newsletters.

spot_img